New material to meet the demands of delivering life-enhancing medications

Covestro LLC introduces Makrolon® Rx3440 polycarbonate for better performing IV connectors

Reliable IV connections
Makrolon® Rx3440 polycarbonate from Covestro LLC demonstrates superior durability and oncology drug resistance for reliable IV connections, as well as the company’s ongoing innovation in healthcare.

Anaheim, Calif., February 6, 2018 — When a patient needs life-saving medical treatment, everything must work as designed, right down to the plastic used in luers and other IV connectors. However, not all materials are created equal. Inferior materials often cannot withstand cleaning agents, nor can they tolerate aggressive solvents found in oncology drugs and other treatments. The result: cracking and damage to critical components.

Makrolon® Rx3440 polycarbonate, a new medical polycarbonate from Covestro LLC, offers superior durability and chemical resistance to help prevent cracking so that health care professionals can more safely deliver oncology drugs to patients.

Compared with other transparent resins used for IV access components, comprehensive lab testing has shown that Makrolon® Rx3440 polycarbonate provides best-in-class chemical and oncology drug resistance. This material also demonstrates the best retention of stress to provide more reliable IV connections.

Makrolon® Rx3440 polycarbonate also offers several other advantages for medical OEMs, including:

  • Biocompatible according to ISO 10993-1 and USP Class IV standards
  • Greater structural integrity to allow for thin-walled designs
  • Toughness to resist mishandling
  • Dimensional stability in shipping and storage


A Covestro-designed testing apparatus was instrumental in the development of Makrolon® Rx3440 polycarbonate and is available to test the chemical resistance of customers’ luer connectors. The novel apparatus provides:

  • Immersion under real-life loading
  • Adjustable force, allowing accelerated testing


“We’ve leveraged our knowledge of this highly regulated market to formulate a material that serves an important need, yet requires minimal validation and requalification by OEMs,” said George Paleos, vice president, global industrial marketing, Polycarbonates, Covestro LLC. “Importantly, we’re also able to provide customer support every step of the way from design and material selection to final approval.”

For more information about Makrolon® Rx3440 polycarbonate, including testing data, visit: www.MakrolonRx3440.com.

Attendees at MD&M West Conference and Exposition (mdmwest.mddionline.com), Feb. 6-8, in Anaheim, California, can visit the Covestro booth (#2221) for more information about the company’s medical applications and materials.

About Covestro LLC:

Covestro LLC is one of the leading producers of high-performance polymers in North America and is part of the global Covestro business, which is among the world’s largest polymer companies with 2016 sales of EUR 11.9 billion. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, construction, wood processing and furniture, electrical and electronics, and medical industries. Other sectors include sports and leisure, cosmetics and the chemical industry itself. Covestro has 30 production sites worldwide and employed approximately 15,600 people at the end of 2016.

Find more information at www.covestro.us or www.plastics.covestro.com.

Makrolon® is a registered trademark of Covestro Group.

Covestro Contact:

John Skabardonis, Phone: +1 412 413 5444
John.Skabardonis@covestro.com

# # #

This press release may contain forward-looking statements based on current assumptions and forecasts made by Covestro AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Covestro’s public reports which are available on the Covestro website at www.covestro.com. Covestro assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Editor’s Note: Follow news from Covestro on Twitter:
www.twitter.com/CovestroGroup